Ian MacLachlan

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    J Virol 82:5664-8. 2008
  2. ncbi Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA, USA
    Vaccine 26:6894-900. 2008
  3. ncbi Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    PLoS Pathog 4:e1000225. 2008
  4. ncbi Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    Thomas W Geisbert
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Virol 83:7296-304. 2009
  5. ncbi Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA 02118, USA
    Lancet 375:1896-905. 2010
  6. ncbi Postexposure treatment of Marburg virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts 02118, USA
    Emerg Infect Dis 16:1119-22. 2010

Research Grants

  1. RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever
    Ian MacLachlan; Fiscal Year: 2010

Detail Information

Publications6

  1. ncbi Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    J Virol 82:5664-8. 2008
    ..This is the first demonstration of complete postexposure protection against an Ebola virus in nonhuman primates and provides further evidence that postexposure vaccination may have utility in treating exposures to filoviruses...
  2. ncbi Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA, USA
    Vaccine 26:6894-900. 2008
    ..Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection...
  3. ncbi Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    PLoS Pathog 4:e1000225. 2008
    ..Evaluation of CD4+ T cells in all animals showed that the animals that succumbed to lethal ZEBOV challenge had the lowest CD4+ counts, suggesting that CD4+ T cells may play a role in mediating protection against ZEBOV...
  4. ncbi Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    Thomas W Geisbert
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Virol 83:7296-304. 2009
    ..In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species...
  5. ncbi Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA 02118, USA
    Lancet 375:1896-905. 2010
    ..We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever...
  6. ncbi Postexposure treatment of Marburg virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts 02118, USA
    Emerg Infect Dis 16:1119-22. 2010
    ..We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals were protected when the vaccine was administered 48 h postinfection...

Research Grants1

  1. RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever
    Ian MacLachlan; Fiscal Year: 2010
    ....